TILT-123

Phase 2

MERCK (MRK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

MRKPhase 2$281.2B

TILT-123 Phase 2 Est. Readout

TILT-123• Platinum-refractory Ovarian Carcinoma29

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Platinum-refractory Ovarian Carcinoma

View Full Landscape

Drug Information

Target Indication

Platinum-refractory Ovarian Carcinoma

Clinical Trial

NCT05271318

Last updated: 9/9/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

EnpatoranPhase 3

Systemic Lupus Erythematosus (SLE)

EstrogensPhase 3

Infertility

EpacadostatPhase 3

Gastric Adenocarcinoma

ezetimibe (plus simvastatin)Phase 3

Atherosclerosis

Golimumab 50 mg SCPhase 3

Arthritis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts